資源描述：
《注射型唑來膦酸鹽治療絕經(jīng)后骨質(zhì)疏松癥臨床觀察.doc》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、注射型卩坐來麟酸鹽治療絕經(jīng)兀骨質(zhì)疏松癥臨床觀察［摘要］目的探討
2、
3、坐來麟酸注射液治療絕經(jīng)示骨質(zhì)疏松癥的臨床療效，評價(jià)其安全性。方法將絕經(jīng)后骨質(zhì)疏松癥患者70例隨機(jī)分成治療組和對照組，各35例，兩組在年齡、絕經(jīng)年限等方面比較差異均無統(tǒng)計(jì)學(xué)意義(P>0.05)。治療組給予啤來麟酸注射液(密間達(dá))5mg/100mL靜滴1次，同時(shí)口服鈣爾奇片-。對照組僅給予口服鈣爾奇片，兩組受試者均連續(xù)服藥10個月。觀察骨痛、骨密度變化及安全性指標(biāo)。結(jié)果治療示治療組骨痛癥狀明顯緩解,兩組總有效率比較并異有統(tǒng)計(jì)學(xué)意義(P<0.05)；骨密度檢測治療組增加與對照組比較差
4、異有統(tǒng)計(jì)學(xué)意義(P<0.05)；治療期間治療組無新發(fā)骨折。結(jié)論I!坐來麟酸注射液對絕經(jīng)后骨質(zhì)疏松癥患者具有緩解骨痛、增加骨密度、提高生活質(zhì)量、減少骨折發(fā)生的作用，是一種有效、安全的藥物。［關(guān)鍵詞］哇來憐酸；骨質(zhì)疏松；絕經(jīng)后；骨密度［中圖分類號］R681［文獻(xiàn)標(biāo)識碼］A［文章編號］1673-7210(2012)01(c)-0073-02ClinicalobservationofZoledronicAcidSaJtInjectioninthetreatmentofpostmenopausalosteoporosisSONGYanyunlXINJi
5、an21.ShandongAthleteRehabilitationCenter,ShandongProvince,Ji'nan250102,China;2.TheAffiliatedHospitalofShandongUniversityofTraditiontilChineseMedicine,ShandongProvince,Ji'nan250011,China［Abstract］ObjectiveToexploretheclinicalefficacyofZoledronicAcidInjectioninthetreatmentofp
6、ostmenopausalosteoporosisandtoassessitssafety.Methods70patientswithpostmenopausalosteoporosiswererandomlydividedintotreatmentgroupandcontrolgroup,with35casesineachgroupandnosignificantdifferencesinage,menopauseandsoon(P>0.05).Forthetreatmentgroup,5mg/100mLofZoledronicAcidIn
7、jection(Adasta)wasinfusedoncewhileCaltratewastakenora11y?Forthecontrolgroup,onlyCaltratewastakenorally?Subjectsofthetwogroupstookmedicincfor10consecutivemonths?Thenbonepain,bonemineraldensity(BMD)varianeeandsafetyindicatorswereobserved?ResultsAftertreatment,thebonepainofthe
8、treatmentgroupwasmitigatedgreatly,thediffereneeofthetotaleffectiveratebetweenthetwogroupswassignifiednt(P<0.05);theBMDincreasewassignifiedntcomparedwiththatofthecontrolgroup(P<0?05);duringthetreatment,nonewfracturesoccurredinthetreatmentgroup?Cone1usionZoledronicAcidInjecti
9、oncaneasethebonepainofpostmenopausalosteoporosis,improvelifequa!ity,increaseBMDandreducetheoccurrencesoffractures;itisaneffectiveandsafedrug>［Keywords］ZoledronicAcid;Osteoporosis;Postmenopausal;Bonemineraldensity原發(fā)性骨質(zhì)疏松癥是以骨量減少，骨小梁變細(xì)、數(shù)量減少，皮質(zhì)骨多孔、變薄為特征，導(dǎo)致骨的脆性增加和易于發(fā)生骨折為特征的全身性骨病
10、，包括絕經(jīng)后骨質(zhì)疏松癥和老年性骨質(zhì)疏松癥。研究發(fā)現(xiàn)，雙麟酸鹽類藥物可明顯增加絕經(jīng)后骨質(zhì)疏松癥患者的骨密度，降低骨折發(fā)生率。2009年10月?2010年11月我院對3
